Results 51 to 60 of about 222,667 (349)

Personalizing HIV therapy, mission impossible? [PDF]

, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity

Фармация и фармакология (Пятигорск)
One of the new classes of drugs for weight loss in overweight and obesity, the safety and efficacy of which have been proven in large-scale studies, are glucagon-like peptide-1 receptor agonists (GLP-1 agonists).
A. S. Ametov, P. A. Bely, K. Y. Zaslavskaya, E. A. Rogozhina, V. S. Shcherbakova, Y. G. Kazaishvili, A. V. Taganov, T. G. Bodrova, E. S. Mishchenko, K. N. Koryanova, L. I. Shcherbakova   +10 more
doaj   +1 more source

In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration

Drug Delivery, 2017
Diltiazem hydrochloride (DTZ) is a calcium channel antagonist depicted by extensive first pass metabolism and low oral bioavailability. The aim of this work was to develop niosomes for potential nasal delivery of DTZ.
H. O. Ammar, M. Haider, M. Ibrahim, N. M. El Hoffy   +3 more
doaj   +1 more source

Pharmacokinetic Profile of Norfloxacin in Pigeons

Revista de Ciências Agroveterinárias, 2023
Through this work, the pharmacokinetics of Norfloxacin in pigeons were explored by using six healthy male pigeons as the subjects for this study. The pharmacokinetic indices of orally administered Norfloxacin were obtained by microbiological assay and ...
Mustafa Ahmed Jasim Al-jumaili, Nibras Naeb Abdulhamza Alabbas, Orooba M. S. Ibrahim   +2 more
doaj   +1 more source

Advanced signal processing methods in dynamic contrast enhanced magnetic resonance imaging [PDF]

, 2015
Tato dizertační práce představuje metodu zobrazování perfúze magnetickou rezonancí, jež je výkonným nástrojem v diagnostice, především v onkologii. Po ukončení sběru časové sekvence T1-váhovaných obrazů zaznamenávajících distribuci kontrastní látky v ...
Bartoš, Michal
core  

Systematic review and meta-analysis of the pharmacokinetics of benznidazole in the treatment of Chagas disease [PDF]

, 2016
Chagas disease is a neglected parasitic illness affecting approximately 8 million people, predominantly in Latin America. Benznidazole is the drug of choice for treatment, although its availability has been limited.
Ayers, Dieter, Ferrero, Luis, Gold, Silvia, Kanters, Steve, Krolewiecki, Alejandro Javier, Mills, Edward, Peregrina Lucano, Alejandro A., Wiens, Matthew O.   +7 more
core   +1 more source

Digital twins to accelerate target identification and drug development for immune‐mediated disorders

FEBS Open Bio, EarlyView.
Digital twins integrate patient‐derived molecular and clinical data into personalised computational models that simulate disease mechanisms. They enable rapid identification and validation of therapeutic targets, prediction of drug responses, and prioritisation of candidate interventions.
Anna Niarakis, Philippe Moingeon
wiley   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source